In the claims:

Please cancel claims 1-5 and 14-18 without prejudice.

The following claims 6, 10, 11, 12, and 13 have been amended to read:

A7

6. (Amended) A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to a synergistically effective amount of agonistic anti-DR5 receptor antibody and CPT-11.

7. (As filed) The method of claim 6 wherein said anti-DR5 receptor antibody is a monoclonal antibody.

8. (As filed) The method of claim 7 wherein said anti-DR5 receptor monoclonal antibody comprises a chimeric antibody.

9. (As filed) The method of claim 7 wherein said anti-DR5 receptor monoclonal antibody comprises a human antibody.

A8

10. (Amended) The method of claim 6 wherein said agonistic anti-Apo-2 ligand ~~receptor antibody~~ is an antibody which cross-reacts with more than one Apo-2 ligand receptor.

11. (Amended) The method of claim 6 further comprising exposing the cancer cells to one or more growth inhibitory agents.

12. (Amended) The method of claim 6 further comprising exposing the cells to radiation.

13. (Amended) The method of claim 6 wherein the cancer cells comprise colorectal cancer cells.

Please add the following claims:

A9

19-19. A method of inducing apoptosis in mammalian cancer cells

comprising exposing mammalian cancer cells to a synergistically effective amount of agonistic anti-DR5 receptor antibody and CPT-11, wherein said agonistic anti-DR5 receptor antibody is a monoclonal antibody capable of inducing apoptosis in a mammalian cell expressing DR5 receptor.

20. The method of claim 19 wherein said mammalian cancer cells are exposed to said antibody and CPT-11 *in vitro*.

21. The method of claim 19 wherein said mammalian cancer cells are exposed to said antibody and CPT-11 *in vivo*.

22. The method of claim 19 wherein said agonistic anti-DR5 receptor antibody is a chimeric antibody.

23. The method of claim 22 wherein said chimeric antibody includes a variable or hypervariable domain of the anti-DR5 monoclonal antibody secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534.

24. The method of claim 19 wherein said agonistic anti-DR5 antibody binds to the same DR5 receptor epitope to which the anti-DR5 monoclonal secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534 binds.

25. The method of claim 19 wherein said agonistic anti-DR5 antibody is a human antibody.

26. The method of claim 19 wherein said agonistic anti-DR5 antibody specifically binds to DR5 receptor.

27. The method of claim 26 wherein said antibody has a DR5 receptor binding affinity of 10^8 M^{-1} to 10^{12} M^{-1}.

28. The method of claim 19 wherein said agonistic anti-DR5 receptor antibody inhibits binding of Apo-2 ligand to DR5 receptor.

29. The method of claim 19 wherein said agonistic anti-DR5 receptor antibody is a cross-reactive antibody which binds DR5 receptor and one or more other Apo-2 ligand receptors.

30. The method of claim 19 wherein said antibody is expressed in a recombinant host cell selected from the group consisting of a CHO cell, yeast cell and *E. coli*.

31. The method of claim 19 wherein said mammalian cancer cells are colon cancer cells or colorectal cancer cells.

32. A method of inducing apoptosis in mammalian colon or colorectal cancer cells comprising exposing mammalian colon or colorectal cancer cells to a synergistically effective amount of agonistic anti-DR5 receptor antibody and CPT-11, wherein said agonistic anti-DR5 receptor antibody is a monoclonal antibody capable of inducing apoptosis in a mammalian cell expressing DR5 receptor.

33. The method of claim 32 wherein said agonistic anti-DR5 receptor antibody is a chimeric antibody.

34. The method of claim 33 wherein said chimeric antibody includes a variable or hypervariable domain of the anti-DR5 monoclonal antibody secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534.

35. The method of claim 32 wherein said agonistic anti-DR5 antibody binds to the same DR5 receptor epitope to which the anti-

DR5 monoclonal secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534 binds.

36. The method of claim 32 wherein said agonistic anti-DR5 antibody is a human antibody.

37. The method of claim 32 wherein said agonistic anti-DR5 antibody specifically binds to DR5 receptor.

38. The method of claim 37 wherein said antibody has a DR5 receptor binding affinity of 10^8 M^{-1} to 10^{12} M^{-1}.

39. The method of claim 32 wherein said agonistic anti-DR5 receptor antibody inhibits binding of Apo-2 ligand to DR5 receptor.

40. The method of claim 32 wherein said agonistic anti-DR5 receptor antibody is a cross-reactive antibody which binds DR5 receptor and one or more other Apo-2 ligand receptors.

41. The method of claim 19 wherein said antibody is expressed in a recombinant host cell selected from the group consisting of a CHO cell, yeast cell and *E. coli*.

42. A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to a synergistically effective amount of agonistic anti-DR5 receptor antibody and CPT-11, wherein said agonistic anti-DR5 receptor antibody is a monoclonal antibody capable of inducing apoptosis in a mammalian cell expressing DR5 receptor and binds to the same DR5 receptor epitope to which the anti-DR5 monoclonal secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534 binds.

43. A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to a synergistically effective amount of agonistic anti-DR5 receptor antibody and CPT-11, wherein said agonistic anti-DR5 receptor antibody is a chimeric antibody capable of inducing apoptosis in a mammalian cell expressing DR5 receptor and includes a variable or hypervariable domain of the anti-DR5 monoclonal antibody secreted by the hybridoma deposited as ATCC accession no. HB-12456 or by the hybridoma deposited as ATCC accession no. HB-12534. ---